BBC

Virtus LifeSci Biotech Clinical Trials ETF [BBC] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

BBC Stock Summary

Top 10 Correlated ETFs

BBC

Top 10 Correlated Stocks

BBC

In the News

BBC Financial details

Company Rating
-
Market Cap
11.64M
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
0.08
Dividend %
0.31%
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
20.33%
SMA50
36.48%
SMA100
63.78%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
16.88-31.99
52W High
-2.94%
52W Low
+88.06%
RSI
72.3
Rel Volume
1.6
Avg Volume
4.55K
Volume
7.3K
Perf Week
3.83%
Perf Month
23.42%
Perf Quarter
62.12%
Perf Half Y
85.51%
-
-
-
-
Beta
0.93
-
-
Volatility
0.61%, 2.16%
Prev Close
-1.31%
Price
30.09
Change
-4.17%

BBC Financial Performance

BBC Dividend History

BBC Frequently Asked Questions

What is Virtus LifeSci Biotech Clinical Trials ETF stock symbol ?

Virtus LifeSci Biotech Clinical Trials ETF is a US stock and trading under the symbol BBC

What is Virtus LifeSci Biotech Clinical Trials ETF stock quote today ?

Virtus LifeSci Biotech Clinical Trials ETF stock price is $30.09 today.

Is Virtus LifeSci Biotech Clinical Trials ETF stock public?

Yes, Virtus LifeSci Biotech Clinical Trials ETF is a publicly traded company.

Something similar

Top by Market Cap
0YXG.L
NVDA
ABEC.DE
MSF.DE
GOOG
Top Correlated ETFs
XBI
LABU
PTH
SLV
CEF
Top Correlated Stocks
IMTX
EDIT
NANO.PA
IWG.L
0QAV.L
Similar Market Cap
XFI.TO
BSGM
HEET
YPS
LMFA

Company Profile

Financial Services Asset Management
  • Volume Average 4.55K
  • Market Capitalization 11.64M
  • Headquarters US
  • IPO Date 2014-12-17

Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.